Dietary supplements from the computer
Artificial intelligence was first involved in the development of the BUD
Anna Stavina, XX2 century, based on EurekAlert! – Artificial intelligence enters the nutraceutical industry
In March 2016, Insilico Medicine, a company specializing in the use of modern technologies in drug development, began cooperation with Life Extension. The aim of the joint work was to apply the latest achievements of bioinformatics and deep learning in the search for substances of natural origin that can slow down or even reverse the cellular and molecular mechanisms of aging.
A year later, on March 1, 2017, Life Extension announced the launch of a new line of GEROPROTECT dietary supplements. The composition of the first product from this line, a dietary supplement called Ageless Cell, was formed using Insilico Medicine algorithms. The substances included in Ageless Cell are classified as "Generally Recognized as Safe" (GRAS).
The first results of a study of biomarkers of human aging and a new product were presented at the RE•WORK – Deep Learning in Healthcare summit, held in London from February 28 to March 1, 2017.
CEO of Insilico Medicine Alex Zhavoronkov congratulated the partner company on the creation of the first biologically active supplement, the components of which were selected using artificial intelligence (AI).
Andrew Swick, Life Extension's First Vice President for Scientific Affairs, Research and New Product Development, said: "Our collaboration with Insilico Medicine has led to a new approach in the development of anti-aging supplements. We used artificial intelligence and sophisticated biotechnological algorithms, and as a result, we received the first biologically active supplement of its kind, developed with the participation of AI."
The volume of the international market of dietary supplements in 2014, according to Transparency Market Research, amounted to 165.62 billion US dollars by 2021. it is expected to grow to 278.92 billion. However, numerous papers published in scientific journals have demonstrated that many dietary supplements are ineffective in preventing diseases. Another important problem of biomedical research was the limited applicability in medicine of the results of tests conducted on animals. Approximately 95% of anticancer drugs fail in clinical trials, although they have demonstrated effectiveness in experiments on mice or rabbits. The goal of the partnership between Insilico Medicine and Life Extension was to reduce the list of useless dietary supplements and search for those compounds that are most likely to be useful for people.
Scientists from Insilico Medicine have developed a database in which the results of biomedical research were recorded and the most promising chemical compounds in terms of prolonging life and combating aging were noted. Then the database was processed with a special tool based on deep learning technologies. This made it possible to identify the molecules that are most likely to be effective and safe when used in humans.
In a study published in Aging (Aliper et al., In search for geroprotectors: in silico screening and in vitro validation of signalome-level mimetics of young healthy state), a short list of compounds likely to protect against aging was proposed. Another paper prepared by scientists from Insilico Medicine and published in the journal Nature Communications (Ozerov et al., In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development) described a tool used to find minimal differences in gene expression in the tissues of young and old organisms, as well as in healthy and diseased tissues.
Portal "Eternal youth" http://vechnayamolodost.ru
06.03.2017